Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of
about 36 subjects with moderate to severe Chronic Spontaneous Urticaria.